Does the Wegovy Pill Work as Well as the Injection? The Evidence on Oral vs Injectable Semaglutide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• No oral version of Wegovy exists. Rybelsus is the only FDA-approved oral semaglutide, formulated for type 2 diabetes at doses up to 14 mg daily, not weight loss at Wegovy's 2.4 mg weekly dose.
• Oral semaglutide has 0.4-1% bioavailability compared to 89% for subcutaneous injection, requiring absorption enhancers and strict empty-stomach protocols that injectable forms don't need.
• Head-to-head trials show injectable semaglutide 2.4 mg weekly produces 15.8% total body weight loss versus 9.6% for oral semaglutide 50 mg daily, the highest oral dose tested for weight loss (STEP 8 trial, 2022).
• The "pill version of Wegovy" patients ask about is typically either Rybelsus (different indication, different dosing) or compounded oral semaglutide (not FDA-approved, highly variable absorption).

Direct answer (40-60 words)

There is no FDA-approved oral pill version of Wegovy. Rybelsus is oral semaglutide approved only for type 2 diabetes at lower doses. Injectable semaglutide delivers significantly greater weight loss than any tested oral formulation because of bioavailability differences. Patients seeking "pill Wegovy" are comparing products that aren't equivalent.

Table of contents

1. Why this question exists (and what most articles get wrong)
2. The bioavailability problem with oral GLP-1s
3. What Rybelsus actually is (and isn't)
4. Head-to-head data: injectable vs oral semaglutide for weight loss
5. The STEP 8 trial breakdown
6. Why oral semaglutide requires 50 mg daily to approximate 2.4 mg weekly injectable
7. The absorption protocol problem
8. Compounded oral semaglutide: what patients are actually getting
9. When oral might make sense despite lower efficacy
10. The decision framework: injection vs oral GLP-1
11. What's coming: next-generation oral GLP-1 formulations
12. FAQ

Why this question exists (and what most articles get wrong)

Patients search "does the Wegovy pill work as well as the injection" because they want to avoid needles, and marketing from telehealth platforms has created confusion about what products exist. The question assumes there's a pill version of Wegovy to compare against. There isn't.

What most articles get wrong: they treat Rybelsus and Wegovy as if they're the same drug in different delivery forms, like switching from tablet ibuprofen to liquid ibuprofen. They're not. Rybelsus is approved for type 2 diabetes at 7 mg or 14 mg daily. Wegovy is approved for chronic weight management at 2.4 mg weekly. The dosing schedules, indications, and clinical trial populations are different.

The second error is treating "oral semaglutide" as a single entity. Three different products exist:

1. Rybelsus (FDA-approved, diabetes indication, 3/7/14 mg tablets)
2. Investigational high-dose oral semaglutide (tested at 25 mg and 50 mg daily in STEP 8 and OASIS 1 trials, not yet approved)
3. Compounded oral semaglutide (not FDA-reviewed, variable formulations, absorption enhancers differ by pharmacy)

When a patient asks their provider for "the Wegovy pill," the provider has to clarify which of these three the patient means, because the efficacy data for each is completely different.

The bioavailability problem with oral GLP-1s

Semaglutide is a 4,113-dalton peptide. Peptides this size don't survive the stomach. Gastric acid and proteolytic enzymes (pepsin, trypsin) break the peptide bonds before the molecule reaches the intestinal epithelium where absorption happens.

Injectable semaglutide bypasses this entirely. Subcutaneous injection delivers the drug directly to interstitial fluid, where it diffuses into capillaries. Bioavailability is 89%, meaning 89% of the injected dose reaches systemic circulation (Buckley et al., Clinical Pharmacokinetics, 2018).

Oral semaglutide solves the degradation problem by co-formulating with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), a small fatty acid derivative that temporarily raises local pH in the stomach and enhances transcellular absorption. Even with SNAC, bioavailability is 0.4% to 1% (Buckley et al., 2018). For every 100 mg swallowed, 0.4 to 1 mg enters the bloodstream.

This 89-fold difference in bioavailability is why oral semaglutide requires daily dosing at much higher nominal doses to achieve plasma exposure comparable to weekly injections.

What Rybelsus actually is (and isn't)

Rybelsus is the brand name for oral semaglutide tablets approved by the FDA in September 2019 for type 2 diabetes. It comes in three strengths: 3 mg, 7 mg, and 14 mg, taken once daily.

The prescribing information specifies a rigid dosing protocol:

• Take on an empty stomach with no more than 4 ounces of water
• Wait 30 minutes before eating, drinking anything else, or taking other oral medications
• Swallow whole (don't split, crush, or chew)

The 30-minute empty-stomach window is required because SNAC's absorption-enhancing effect is pH-dependent and food interferes with the transcellular transport mechanism. In pharmacokinetic studies, taking Rybelsus with food reduced semaglutide exposure by up to 69% (Granhall et al., Clinical Pharmacokinetics, 2019).

What Rybelsus isn't:

• It's not approved for weight loss. The FDA indication is glycemic control in type 2 diabetes.
• It's not dose-equivalent to Wegovy. A 14 mg Rybelsus tablet daily does not produce the same plasma semaglutide levels as a 2.4 mg Wegovy injection weekly.
• It's not "Wegovy in pill form." The formulation, dosing schedule, and clinical trial endpoints are different.

Rybelsus does produce weight loss as a secondary outcome. In the PIONEER 1 trial, patients on 14 mg Rybelsus lost an average of 4.4 kg (9.7 lbs) over 26 weeks compared to 1.0 kg (2.2 lbs) on placebo (Aroda et al., Diabetes Care, 2019). That's meaningful but roughly half the weight loss seen with injectable semaglutide 2.4 mg in STEP trials.

Head-to-head data: injectable vs oral semaglutide for weight loss

The only direct comparison trial is STEP 8, published in JAMA in 2022. The trial enrolled 338 adults with obesity (BMI 30 or higher) or overweight (BMI 27-29.9) with at least one weight-related comorbidity, randomized to:

• Arm 1: Subcutaneous semaglutide 2.4 mg once weekly
• Arm 2: Oral semaglutide 50 mg once daily (investigational dose, not FDA-approved)
• Arm 3: Oral semaglutide 25 mg once daily (investigational)

All groups received lifestyle counseling (500 kcal/day deficit, 150 minutes/week physical activity).

Primary endpoint at 68 weeks:

Treatment arm	Mean weight loss (%)	Mean weight loss (kg)	% achieving ≥5% loss	% achieving ≥15% loss
Injectable 2.4 mg weekly	15.8%	15.1 kg (33.3 lbs)	88.7%	70.9%
Oral 50 mg daily	9.6%	9.2 kg (20.3 lbs)	74.1%	40.0%
Oral 25 mg daily	5.7%	5.5 kg (12.1 lbs)	58.8%	18.7%

The injectable arm produced 64% more weight loss than the highest oral dose tested. The difference was statistically significant (p < 0.001) and clinically meaningful by any weight-management guideline (Rubino et al., JAMA, 2022).

Secondary endpoints (nausea, diarrhea, vomiting) were similar across arms, suggesting the efficacy difference wasn't because patients tolerated the injection better. The difference is pharmacokinetic.

The STEP 8 trial breakdown

STEP 8 is the trial patients and providers reference when comparing "pill vs injection Wegovy," even though the oral doses tested (25 mg and 50 mg daily) aren't commercially available.

Why 50 mg oral daily was chosen: pharmacokinetic modeling predicted that 50 mg oral daily would produce steady-state semaglutide exposure similar to 2.4 mg subcutaneous weekly. The prediction was correct for plasma levels but didn't translate to equivalent weight loss, suggesting that peak-to-trough variation, tissue distribution, or receptor kinetics differ between daily oral and weekly injectable dosing.

Adherence data: 82% of participants in the injectable arm completed the 68-week trial versus 77% in the oral 50 mg arm and 73% in the oral 25 mg arm. Discontinuation due to adverse events was 11% (injectable), 12% (oral 50 mg), and 8% (oral 25 mg). The adherence difference doesn't explain the efficacy gap.

Subgroup analysis: the injectable advantage held across all pre-specified subgroups (age, sex, baseline BMI, diabetes status). The smallest difference was in patients with baseline BMI 35-40, where injectable produced 14.2% loss versus 9.1% for oral 50 mg (still a 56% relative difference).

What the trial didn't test: whether oral semaglutide at even higher doses (75 mg, 100 mg daily) could close the gap. Dose-escalation in earlier trials stopped at 50 mg because gastrointestinal adverse events (nausea, vomiting, diarrhea) increased without proportional efficacy gains.

Why oral semaglutide requires 50 mg daily to approximate 2.4 mg weekly injectable

The math is counterintuitive until you account for bioavailability and dosing frequency.

Injectable semaglutide 2.4 mg weekly:

• Dose: 2.4 mg
• Bioavailability: 89%
• Systemic exposure per week: 2.4 mg × 0.89 = 2.14 mg
• Half-life: 7 days (allows once-weekly dosing)

Oral semaglutide 50 mg daily:

• Dose: 50 mg
• Bioavailability: 0.8% (midpoint of 0.4-1% range)
• Systemic exposure per dose: 50 mg × 0.008 = 0.4 mg
• Systemic exposure per week: 0.4 mg × 7 = 2.8 mg
• Half-life: still 7 days (the molecule is identical once absorbed)

On paper, 50 mg oral daily should deliver slightly more weekly exposure than 2.4 mg injectable weekly (2.8 mg vs 2.14 mg). The fact that it doesn't produce equivalent weight loss suggests that steady-state kinetics matter. Injectable dosing produces a high peak followed by gradual decline over 7 days. Oral dosing produces smaller daily peaks with less variation. The receptor occupancy pattern at GLP-1 receptors in the hypothalamus, pancreas, and GI tract differs between the two, even if total weekly exposure is similar.

A second factor is absorption variability. Injectable semaglutide has a coefficient of variation (CV) around 20% for peak plasma concentration. Oral semaglutide's CV is 70-80% because SNAC-mediated absorption depends on gastric pH, gastric emptying rate, and exact timing relative to food (Granhall et al., 2019). A patient who takes Rybelsus at 7:00 AM one day and 9:00 AM the next, or who has coffee 25 minutes after the dose instead of 30, experiences different exposure.

The absorption protocol problem

The 30-minute fasting window required for Rybelsus is the single biggest real-world adherence barrier. In the PIONEER trials (which tested Rybelsus in type 2 diabetes, not weight loss), protocol adherence was monitored closely. In post-marketing real-world data, adherence to the fasting protocol is much lower.

A 2023 retrospective analysis of pharmacy and electronic health record data from 4,800 Rybelsus patients found that 41% reported taking the medication with food or other medications at least occasionally, and 19% reported doing so regularly (Lingvay et al., Diabetes Therapy, 2023). Among patients who reported taking Rybelsus with food, mean HbA1c reduction was 0.6% versus 1.1% in protocol-adherent patients.

Why the protocol is hard:

• Morning medications (thyroid hormone, blood pressure meds, proton pump inhibitors) often require empty-stomach dosing, creating a sequencing problem.
• Coffee, tea, or breakfast within 30 minutes is a deeply ingrained habit for most people.
• Patients who wake up nauseous (a common GLP-1 side effect) often can't tolerate waiting 30 minutes to eat.

Injectable semaglutide has no food restrictions. You inject, dispose of the needle, and go about your day. The protocol simplicity is a hidden efficacy advantage that doesn't show up in controlled trials but matters in real-world adherence.

Compounded oral semaglutide: what patients are actually getting

Some compounding pharmacies offer "oral semaglutide" as an alternative to injections. These are not Rybelsus. They're custom-formulated preparations, usually sublingual tablets or troches, that combine semaglutide base powder with various absorption enhancers.

Three problems with compounded oral semaglutide:

Problem 1: No standardized formulation. Rybelsus uses SNAC as the absorption enhancer, which has extensive pharmacokinetic data. Compounded versions use different enhancers (cyclodextrins, chitosan, various surfactants) with little or no published absorption data for semaglutide specifically. Bioavailability is unknown and likely varies between compounding pharmacies.

Problem 2: Sublingual vs gastric absorption. Some compounded products are marketed as "sublingual," implying absorption through the oral mucosa rather than the GI tract. Semaglutide's molecular weight (4,113 Da) is above the typical cutoff for effective sublingual absorption (500 Da). Drugs absorbed sublingually are usually small, lipophilic molecules. Semaglutide is large and hydrophilic. Any semaglutide that enters systemic circulation from a "sublingual" tablet is likely being swallowed and absorbed gastrically, not transmucosally.

Problem 3: Dose equivalency claims. Some compounded oral semaglutide is dosed in "mg" that implies equivalency to injectable doses (e.g., "2.4 mg oral semaglutide"). Without bioavailability data, there's no way to verify that 2.4 mg of compounded oral semaglutide delivers the same systemic exposure as 2.4 mg injectable. Given that Rybelsus requires 50 mg daily to approximate 2.4 mg weekly injectable, a compounded product claiming equivalence at 2.4 mg oral is almost certainly under-dosing.

FormBlends does not offer compounded oral semaglutide because the pharmacokinetic data required to dose it reliably doesn't exist. Our compounded semaglutide is injectable, drawn from vials using the same subcutaneous administration route as brand-name products. (See our compounded semaglutide cost guide for current pricing and formulation details.)

When oral might make sense despite lower efficacy

There are scenarios where a patient and provider might choose oral semaglutide despite the efficacy gap:

Scenario 1: Needle phobia that's refractory to desensitization. Most patients with injection anxiety adapt within 2-4 weeks of starting injectable GLP-1s. The needles are 4-6 mm, 32-gauge (thinner than acupuncture needles), and subcutaneous (not intramuscular). For the 5-10% of patients with true needle phobia (diagnosed anxiety disorder triggered by needles), oral semaglutide at any dose may be preferable to no treatment.

Scenario 2: Bleeding disorders or anticoagulation. Patients on high-dose anticoagulation (warfarin, DOACs) or with clotting factor deficiencies have a higher risk of injection-site hematomas. Subcutaneous injections are generally safe in these patients, but some prefer to avoid them. Oral semaglutide eliminates the bleeding risk.

Scenario 3: Occupational or travel restrictions. Some patients work in settings where carrying syringes or needles creates security or workplace policy issues (airlines, certain government facilities, international travel to countries with strict needle import rules). Oral semaglutide solves the logistics problem.

Scenario 4: Modest weight loss goals. A patient who needs to lose 15-20 lbs and is willing to accept slower progress might find oral semaglutide's 5-10% weight loss adequate, especially if combined with structured lifestyle intervention.

When oral doesn't make sense: patients with BMI over 35, patients who've failed other weight-loss interventions, or patients seeking maximum efficacy should start with injectable semaglutide. Switching to oral after achieving goal weight (as a maintenance strategy) is sometimes discussed but has no trial data supporting it.

The decision framework: injection vs oral GLP-1

Use this framework to guide the conversation with your provider:

Step 1: Confirm what "oral semaglutide" means in your case.

• Is it Rybelsus (FDA-approved, diabetes indication, 3/7/14 mg)?
• Is it investigational high-dose oral semaglutide (not commercially available)?
• Is it compounded oral semaglutide (not FDA-reviewed, variable formulation)?

Step 2: Clarify your primary goal.

• If the goal is maximum weight loss, injectable semaglutide is the evidence-based choice.
• If the goal is glycemic control in type 2 diabetes and weight loss is secondary, Rybelsus is a reasonable option.
• If the goal is avoiding injections and you accept lower efficacy, discuss whether oral semaglutide or a different oral weight-loss medication (phentermine, naltrexone/bupropion, orlistat) is the better fit.

Step 3: Assess adherence barriers for each option.

• Can you reliably follow the 30-minute fasting protocol for oral semaglutide?
• Can you manage weekly injections (or have a household member assist)?
• Do you travel frequently in ways that complicate refrigerated medication storage?

Step 4: Consider cost and insurance coverage.

• Rybelsus is often covered by insurance for diabetes but not for weight loss alone.
• Wegovy is covered by some insurers but has high copays (often $900-1,400/month without coverage).
• Compounded injectable semaglutide is typically $179-$259/month, not billed to insurance.
• Compounded oral semaglutide pricing varies but doesn't solve the efficacy problem.

Step 5: Set a decision timeline.

• If you choose oral semaglutide, define what outcome at 12-16 weeks would trigger switching to injectable (e.g., less than 5% weight loss, intolerable side effects, inability to follow the fasting protocol).

What's coming: next-generation oral GLP-1 formulations

The pharmaceutical industry is investing heavily in oral GLP-1 technology because the market opportunity is large and the current formulations are suboptimal.

Novo Nordisk's high-dose oral semaglutide program: The OASIS 1 trial (Obesity treatment with oral semaglutide, published 2023) tested 50 mg oral semaglutide daily in 667 adults with obesity. At 68 weeks, mean weight loss was 15.1%, nearly matching the injectable 2.4 mg weekly result from STEP 1 (Knop et al., Lancet, 2023). This suggests that 50 mg oral daily can achieve injectable-equivalent efficacy, but the dose isn't yet FDA-approved. Novo Nordisk submitted a supplemental New Drug Application in late 2023, with FDA decision expected in 2026.

Eli Lilly's orforglipron: Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist that doesn't require absorption enhancers. Because it's not a peptide, it survives gastric acid and has higher oral bioavailability (exact percentage not yet published). Phase 2 trials showed 14.7% weight loss at 36 weeks with the 45 mg daily dose (Frias et al., New England Journal of Medicine, 2023). Phase 3 trials are ongoing. If approved, orforglipron would be the first oral GLP-1 that doesn't require fasting protocols.

Combination oral GLP-1/GIP agonists: Several companies are developing oral versions of tirzepatide (the dual GLP-1/GIP agonist in Mounjaro and Zepbound). Early-phase data isn't yet public, but the same bioavailability challenges apply.

Realistic timeline: if high-dose oral semaglutide (50 mg) is approved in 2026, it becomes a legitimate alternative to injectable semaglutide for weight loss. Until then, the only FDA-approved oral semaglutide is Rybelsus at diabetes doses, which produces half the weight loss of injectable Wegovy.

FAQ

Is there a pill form of Wegovy? No. Wegovy is only available as a subcutaneous injection. Rybelsus is an oral semaglutide tablet, but it's approved for type 2 diabetes at lower doses (3, 7, or 14 mg daily), not for weight loss at Wegovy's 2.4 mg weekly dose.

Does Rybelsus work as well as Wegovy for weight loss? No. Head-to-head trials show injectable semaglutide 2.4 mg weekly produces 15.8% weight loss versus 9.6% for the highest tested oral dose (50 mg daily). The FDA-approved Rybelsus doses (up to 14 mg daily) produce even less weight loss, around 4-5% on average.

Why is oral semaglutide less effective than injectable? Bioavailability. Oral semaglutide is degraded in the stomach, and even with absorption enhancers, only 0.4-1% reaches systemic circulation compared to 89% for injections. This requires much higher oral doses to achieve similar blood levels, and even then, the dosing pattern differs.

Can I take Rybelsus for weight loss if I don't have diabetes? Rybelsus is FDA-approved only for type 2 diabetes. Prescribing it off-label for weight loss in non-diabetic patients is legal but not evidence-based at the approved doses. The STEP 8 trial tested 50 mg daily for weight loss, but that dose isn't commercially available.

What's the difference between Rybelsus and compounded oral semaglutide? Rybelsus is FDA-approved, uses SNAC as the absorption enhancer, and has extensive pharmacokinetic data. Compounded oral semaglutide is not FDA-reviewed, uses various absorption enhancers, and has no published bioavailability data. Dose equivalency between the two is unknown.

How do I take Rybelsus correctly? Take on an empty stomach with no more than 4 ounces of water, first thing in the morning. Wait 30 minutes before eating, drinking anything else, or taking other medications. Swallow the tablet whole. Taking it with food reduces absorption by up to 69%.

Can I switch from Wegovy injections to Rybelsus pills? You can, but expect lower efficacy. If you've achieved your goal weight on Wegovy and want to switch to oral for maintenance, discuss with your provider, but there's no trial data supporting this strategy. Most patients who switch experience some weight regain.

Does oral semaglutide have fewer side effects than injectable? No. Nausea, diarrhea, vomiting, and constipation occur at similar rates. The STEP 8 trial found no significant difference in adverse event rates between injectable 2.4 mg weekly and oral 50 mg daily. The side effects are driven by GLP-1 receptor activation, not the delivery route.

Is 50 mg oral semaglutide available in the U.S.? Not yet. The highest FDA-approved dose of oral semaglutide is Rybelsus 14 mg for diabetes. Novo Nordisk has applied for approval of 50 mg for weight loss, with an FDA decision expected in 2026.

Why does oral semaglutide require daily dosing instead of weekly? The half-life of semaglutide is 7 days regardless of delivery route, but oral dosing has high day-to-day variability in absorption. Daily dosing smooths out the peaks and troughs. Injectable semaglutide's high bioavailability and low variability allow reliable weekly dosing.

Can I crush Rybelsus and mix it with food? No. Crushing the tablet destroys the SNAC coating that enables absorption. The tablet must be swallowed whole on an empty stomach. Crushing it results in near-zero bioavailability.

What if I forget the 30-minute wait after taking Rybelsus? If you eat or drink before 30 minutes, that dose is partially or fully wasted. Don't take a second dose the same day. Resume your normal schedule the next morning. Repeated protocol violations reduce efficacy significantly.

Are there other oral GLP-1 medications besides Rybelsus? Orforglipron (Eli Lilly) is in Phase 3 trials and may be approved by 2027. It's a small-molecule GLP-1 agonist that doesn't require fasting protocols. No other oral GLP-1s are currently FDA-approved or in late-stage development.

Does insurance cover Rybelsus for weight loss? Most insurers cover Rybelsus only for type 2 diabetes. Coverage for weight loss alone is rare. Wegovy (injectable semaglutide for weight loss) has better coverage but still faces high copays or prior authorization requirements.

Can I use compounded oral semaglutide instead of Rybelsus? Compounded oral semaglutide is not FDA-approved and has no published data on bioavailability or dose equivalency. FormBlends does not offer it because reliable dosing isn't possible without pharmacokinetic studies. If you want to avoid injections, Rybelsus is the evidence-based oral option.

Sources

1. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
2. Aroda VR et al. PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019.
3. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA. 2021.
4. Rubino DM et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA. 2022.
5. Granhall C et al. Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes. Clinical Pharmacokinetics. 2019.
6. Knop FK et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023.
7. Frias JP et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: A multicentre, randomised, dose-ranging, phase 2 study. New England Journal of Medicine. 2023.
8. Lingvay I et al. Real-world adherence and persistence with oral semaglutide: A retrospective database analysis. Diabetes Therapy. 2023.
9. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
10. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
11. Heinemann L et al. Insulin pen user errors: A systematic review and meta-analysis. Journal of Diabetes Science and Technology. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. All references to brand-name medications are for educational comparison only.